Novo Nordisk announced significant developments in its obesity medication portfolio, including major price reductions for existing drugs and a new partnership to develop oral treatments.

The Danish pharmaceutical company said it will cut U.S. list prices for its popular diabetes and weight-loss medications Ozempic and Wegovy by up to 50 percent. The price reductions will take effect in January, with both medications priced at $675 per month.

Separately, Novo Nordisk entered into a partnership agreement with Vivtex worth up to $2.1 billion focused on developing oral obesity drugs. The collaboration represents the company's expansion into alternative delivery methods for weight-loss treatments beyond the current injectable formulations.

The price cuts address ongoing concerns about the affordability of GLP-1 medications, which have seen tremendous demand but remain expensive for many patients. Current list prices for these medications have been significantly higher, making them inaccessible without insurance coverage.

The timing of both announcements reflects Novo Nordisk's strategic positioning in the rapidly growing obesity treatment market, as the company seeks to maintain its competitive advantage while addressing accessibility concerns and expanding its treatment options.